Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: email@example.com
Cadonilimab/Chemotherapy Meets Primary End Point in Phase 3 AK104-303 Trial
Frontline cadonilimab (AK104) and platinum-based chemotherapy improved progression-free survival in patients with recurrent or metastatic cervical cancer.
First-Line Pembrolizumab Shows A Trend Towards Overall Survival in MSI-D/dMMR mCRC
The median overall survival was 77.5 months with frontline pembrolizumab vs 36.7 months with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.
FDA OKs Nirogacestat for Adults Patients With Desmoid Tumors
The FDA has approved nirogacestat as a treatment for adults with progressing desmoid tumors based off findings from the phase 3 DeFi trial.
Copanlisib Will No Longer Be Available in the US for Relapsed Follicular Lymphoma
Manufacturers have announced that they will be withdrawing the new drug application for copanlisib in adult patients with relapsed follicular lymphoma.
FDA Approves Repotrectinib for Adults With Advanced/Metastatic ROS1+ NSCLC
Repotrectinib is now available to treat adults with advanced or metastatic non-small cell lung cancer that harbors a ROS1 fusion.
FDA Launches Priority Review of Liso-Cel in Pretreated CLL/SLL
Lisocabtagene maraleucel is under consideration as a potential treatment option for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Atezolizumab Combo Reduces Risk of Death by 32% Over Bevacizumab/Chemo in Recurrent Cervical Cancer
The median OS achieved with atezolizumab plus bevacizumab and chemotherapy was 32.1 months vs 22.8 months with bevacizumab and chemotherapy alone.
Frontline Selpercatinib Doubles PFS in RET Fusion-Positive NSCLC
In the intention-to-treat population, the median progression-free survival was 24.8 months with selpercatinib vs 11.2 months.
Entrectinib Is Approved for Pediatric Patients with NTRK+ Solid Tumors
The FDA has approved entrectinib to treat pediatric patients ages 1 month and older with NTRK-positive solid tumors.
Pembrolizumab/Chemotherapy is Approved for Neoadjuvant and Adjuvant Resectable Non-Small Cell Lung Cancer
The FDA has approved pembrolizumab with platinum-containing chemotherapy for patients with resectable non–small cell lung cancer, in both the neoadjuvant and adjuvant setting.
Mobocertinib Will No Longer Be Available in US for EGFR Exon 20 Insertion+ NSCLC
Takeda has announced that they will be voluntarily withdrawing mobocertinib for patients with EGFR exon 20 insertion mutation-positive non–small cell lung cancer.
FDA ODAC Panel Votes Against Sotorasib Data in KRAS G12C+ Advanced NSCLC
The FDA Oncologic Drugs Advisory Committee voted 10-to-2 that findings from the phase 3 CodeBreaK 200 trial cannot be reliably interpreted.
Benmelstobart Plus Anlotinib Shows Survival Benefit in ES-SCLC
The benmelstobart combination reduced the risk of death by 39% vs placebo plus chemotherapy in patients with extensive-stage small cell lung cancer.
FDA Approves Momelotinib to Treat Myelofibrosis With Anemia
The FDA has approved momelotinib (Ojjaara) for the treatment of adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, and anemia.
Iruplinalkib Produces Longer PFS Than Crizotinib in Advanced ALK+ NSCLC
The median progression-free survival with iruplinalkib was 27.70 months vs 14.62 months with crizotinib.
Selpercatinib Boosts Progression-Free Survival in RET-Mutant Medullary Thyroid Cancer
Selpercatinib led to improved progression-free survival in patients with advanced or metastatic RET-mutant medullary thyroid cancer.
FDA Grants Priority Review Designation to Enzalutamide for High-Risk nmCSPC
The FDA has granted enzalutamide priority review designation based on data from the phase 3 EMBARK trial.
FDA Approves FoundationOne CDx as a Companion Diagnostic for Niraparib Plus Abiraterone Acetate in BRCA+ mCRPC
FoundationOne CDx is a next-generation sequencing–based in vitro diagnostic device developed to detect substitutions, insertion, and deletion alterations using 1 tissue sample.
Liso-Cel Leads To High Overall Response Rate in Relapsed/Refractory Follicular Lymphoma
Third-line lisocabtagene maraleucel induced a response in 97% of patients with relapsed or refractory follicular lymphoma.
Fruquintinib Under Priority Review for Patients With Previously Treated mCRC
The FDA has launched a priority review of fruquintinib as treatment for adult patients with previously treated metastatic colorectal cancer.
Frontline Pembrolizumab Plus Axitinib Continues To Show Benefits in Advanced ccRCC at 5-Year Follow-Up
A 5-year analysis of the phase 3 KEYNOTE-426 trial showed continued benefit with pembrolizumab plus axitinib for patients with advanced treatment-naïve clear cell renal cell carcinoma.
FOLFOX Demonstrates Comparable Efficacy to Chemoradiation for Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Preoperative FOLFOX demonstrated noninferior efficacy outcomes vs preoperative chemoradiation in locally advanced rectal cancer.
Third-Line GEN-002/Avelumab Elicits Clinical Activity in PD-L1+ Gastric Cancer
Manufacturers believe that GEN-002/avelumab holds promise as a third-line option for patients with gastric cancer and PD-L1 expression.
Lumisight Breast Cancer Detection Device Receives Priority Review Status
The FDA has granted priority review status to a breast cancer optical imaging agent, Lumisight.
Minimally Invasive Distal Pancreatectomy Proves Noninferior to Open Distal Pancreatectomy in Resectable Pancreatic Cancer
Minimally invasive distal pancreatectomy was a safe and effective alternative compared with open distal pancreatectomy in patients with resectable pancreatic cancer.
Capivasertib Demonstrates Potential PFS Advantage in HR+ Advanced Breast Cancer
Combined treatment with capivasertib plus fulvestrant yielded a 5.5-month median progression-free survival for patients with HR+ advanced breast cancer.
Cemiplimab Granted Full Approval For Metastatic Basal Cell Carcinoma
Cemiplimab has received full approval for patients with metastatic basal cell carcinoma. The most common adverse events include fatigue, musculoskeletal pain, rash, diarrhea, and anemia.
Trifluridine/Tipiracil, Plus Bevacizumab Under Priority Review for Refractory mCRC
Trifluridine plus tipiracil, with or without bevacizumab, has been granted priority review status for the treatment of refractory, metastatic colorectal cancer.
Adjuvant Atezolizumab/Bevacizumab Shows Recurrence-Free Survival Benefit Over Active Surveillance in HCC
Combined adjuvant treatment with atezolizumab and bevacizumab was determined to deliver a statistically significant recurrence-free survival benefit to patients with resected hepatocellular carcinoma.
Taletrectinib Shows Promising Response Rates and Intracranial Responses in Select Patients with ROS1+ NSCLC
Patients with TKI-naïve and crizotinib-pretreated ROS-positive non–small cell lung cancer continued to show responses to treatment with taletrectinib.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512